The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research.
A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Developed by Prof. Daniel Offen and Prof. Eldad Melamed of TAU's Sackler Faculty of Medicine and Felsenstein Medical Research Center, the technology is now a patent-pending process that takes stem cells from a patient's own bone marrow and causes them to differentiate into astrocyte-like cells, which are responsible for the well-being of the brain's neurons. The cells release neurotrophic factors, or neuroprotectants, which have been shown to play a key role in reducing the progress of ALS, a debilitating disease characterized by the progressive degeneration of motor neurons, resulting in paralysis of a patient's limbs and organ function.
The research has appeared in the Journal of Stem Cells Reviews and Reports and a number of other publications.
Trials in Jerusalem and Boston
This stem cell technology, says Prof. Offen, represents 10 years of development. Inspired by advances in embryonic stem cell research and its huge potential – but trying to bypass the ethical and safety issues – Prof. Offen and his fellow researchers turned to stem cells derived from a patient's own bone marrow.
After coaxing the cells to differentiate into astrocyte-like cells, whose natural function is to guard the brain's neurons and prevent deterioration, the researchers began testing the concept in animal models. "In the mouse model," Prof. Offen explains, "we were able to show that the bone marrow derived stem cells prevent degeneration in the brain following injection of selective neurotoxins." Researchers also demonstrated that transplantation of these cells increased the survival rate in the mouse model of ALS and significantly delayed the progress of motor dysfunction.
According to Prof. Offen, this is a uniquely successful method for differentiating bone marrow stem cells into astrocyte-like cells without manipulating the genetic material of the cell itself. They are the first team of researchers to demonstrate the efficacy of this technology in vivo in various models of neurodegenerative diseases.
The technology was licensed to BrainStorm Cell Therapeutics that has developed it into a clinical grade product called NurOwn™, which is now being used in a clinical trial at Jerusalem's Hadassah Medical Center. BrainStorm Cell Therapeutics has recently struck an agreement to expand clinical trials to Massachusetts General Hospital in collaboration with the University of Massachusetts Medical School.
Home-grown therapy — and talent
The ongoing clinical studies are aimed at evaluating the safety and the efficacy of this treatment, says Prof. Offen. Because the original cells are drawn from the patients themselves, he adds, the body should have no adverse reactions.
Although the current study targets ALS, these cells have the potential to treat a broad range of neurodegenerative conditions, including Parkinson's and Huntington's diseases. For many conditions, explains Prof. Offen, the current available treatments only attempt to alleviate the symptoms of these diseases rather than repair existing damage.
BrainStorm Cell Therapeutics, the company that is developing the technology, is a spin-off of TAU, Prof. Offen notes. The university has spearheaded the invention involved, and a number of the researchers working within the company graduated from TAU.
American Friends of TelAvivUniversity (www.aftau.org) supports Israel's leading, most comprehensive and most sought-after center of higher learning. Independently ranked 94th among the world's top universities for the impact of its research, TAU's innovations and discoveries are cited more often by the global scientific community than all but 10 other universities.
Internationally recognized for the scope and groundbreaking nature of its research and scholarship, TelAvivUniversity consistently produces work with profound implications for the future.
George Hunka | EurekAlert!
Inactivate vaccines faster and more effectively using electron beams
23.03.2017 | Fraunhofer-Institut für Organische Elektronik, Elektronenstrahl- und Plasmatechnik FEP
Hunting pathogens at full force
22.03.2017 | Helmholtz-Zentrum für Infektionsforschung
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
23.03.2017 | Health and Medicine
23.03.2017 | Physics and Astronomy
22.03.2017 | Materials Sciences